Trial Title:
Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial
NCT ID:
NCT05554341
Condition:
Metastatic Malignant Solid Neoplasm
Refractory Malignant Solid Neoplasm
Conditions: Official terms:
Neoplasms
Paclitaxel
Albumin-Bound Paclitaxel
Nilotinib
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Suspended
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Procedure
Intervention name:
Biopsy
Description:
Undergo biopsy
Arm group label:
Treatment (nilotinib hydrochloride monohydrate, paclitaxel)
Other name:
BIOPSY_TYPE
Other name:
Bx
Intervention type:
Procedure
Intervention name:
Biospecimen Collection
Description:
Undergo collection of blood samples
Arm group label:
Treatment (nilotinib hydrochloride monohydrate, paclitaxel)
Other name:
Biological Sample Collection
Other name:
Biospecimen Collected
Other name:
Specimen Collection
Intervention type:
Procedure
Intervention name:
Computed Tomography
Description:
Undergo CT
Arm group label:
Treatment (nilotinib hydrochloride monohydrate, paclitaxel)
Other name:
CAT
Other name:
CAT Scan
Other name:
Computed Axial Tomography
Other name:
Computerized Axial Tomography
Other name:
Computerized axial tomography (procedure)
Other name:
Computerized Tomography
Other name:
Computerized Tomography (CT) scan
Other name:
CT
Other name:
CT Scan
Other name:
tomography
Intervention type:
Procedure
Intervention name:
Magnetic Resonance Imaging
Description:
Undergo MRI
Arm group label:
Treatment (nilotinib hydrochloride monohydrate, paclitaxel)
Other name:
Magnetic Resonance
Other name:
Magnetic Resonance Imaging (MRI)
Other name:
Magnetic resonance imaging (procedure)
Other name:
Magnetic Resonance Imaging Scan
Other name:
Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
Other name:
MR
Other name:
MR Imaging
Other name:
MRI
Other name:
MRI Scan
Other name:
MRIs
Other name:
NMR Imaging
Other name:
NMRI
Other name:
Nuclear Magnetic Resonance Imaging
Other name:
sMRI
Other name:
Structural MRI
Intervention type:
Drug
Intervention name:
Nilotinib Hydrochloride Monohydrate
Description:
Given PO
Arm group label:
Treatment (nilotinib hydrochloride monohydrate, paclitaxel)
Other name:
AMN 107
Other name:
AMN-107
Other name:
AMN107
Other name:
Nilotinib Monohydrochloride Monohydrate
Other name:
Tasigna
Intervention type:
Drug
Intervention name:
Paclitaxel
Description:
Given IV
Arm group label:
Treatment (nilotinib hydrochloride monohydrate, paclitaxel)
Other name:
Anzatax
Other name:
Asotax
Other name:
Bristaxol
Other name:
Praxel
Other name:
Taxol
Other name:
Taxol Konzentrat
Summary:
This phase II ComboMATCH treatment trial evaluates nilotinib with paclitaxel for the
treatment of patients with solid cancers that are growing, spreading, or getting worse
(progressive) and that have previously been treated with taxane therapies. Nilotinib is
in a class of medications called kinase inhibitors. It works by binding to and blocking
the action of a protein called ABL, which signals tumor cells to multiply. This helps
slow or stop the proliferation of tumor cells. Paclitaxel is a drug that blocks cell
growth by stopping cell division and it may kill tumor cells. Giving nilotinib with
paclitaxel may be effective at treating patients with progressive solid cancers that have
previously been treated with taxane therapies.
Detailed description:
PRIMARY OBJECTIVE:
I. To evaluate the proportion of patients with taxane-refractory advanced malignancies
who have objective responses (OR) to treatment with nilotinib hydrochloride monohydrate
(nilotinib) and paclitaxel.
SECONDARY OBJECTIVE:
I. Collect tissue and provide it to the ComboMATCH registration protocol to assess
concordance between the diagnostic tumor mutation profile generated by the designated
laboratories, the pre-treatment biopsy mutation profile, and the pre-treatment
circulating tumor deoxyribonucleic acid (ctDNA) mutation profile from plasma, as
described in ComboMATCH registration protocol. For this treatment substudy, the outcome
objective will be to report the proportion of cases providing sufficient tissue for that
integrated scientific activity in the ComboMATCH registration protocol.
EXPLORATORY OBJECTIVES:
I. To evaluate progression free survival (PFS) at 6 months on study agents. II. To
identify genomic and transcriptomic determinants of response and resistance in tumor
biopsy specimens and cell-free deoxyribonucleic acid (DNA).
OUTLINE:
Patients receive nilotinib hydrochloride monohydrate orally (PO) twice daily (BID) on
days 1-28 and paclitaxel intravenously (IV) over 1 hour on days 1, 8, and 15 of each
cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable
toxicity. Patients undergo computed tomography (CT) or magnetic resonance imaging (MRI)
throughout the study. Patients also undergo collection of blood samples and tumor biopsy
on study.
After completion of study treatment, patients are followed until disease progression, and
for survival for 3 years from registration.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Patient must be enrolled on the ComboMATCH registration protocol (EAY191) at the
time of registration to the EAY191-E4 study
- Patient must be >= 18 years of age
- Patient must not have any of the following mutations (as determined by the
ComboMATCH registration protocol), which are known to confer sensitivity or
resistance to nilotinib monotherapy:
- KIT: W557R, V559D, V559A, L576P, and K642E
- PDGFR-alpha: D842V
- Patient must have disease that can be safely biopsied and agree to a pre-treatment
biopsy or have archival tissue available from within 12 months prior to the date of
registration on the ComboMATCH registration trial (EAY191)
- NOTE: The current actionable mutation of interest (aMOI)/actionable alteration
list for this treatment trial can be found on the Cancer Trials Support Unit
(CTSU) website
- NOTE: Novel/dynamic aMOI can be submitted for review per the process described
in the ComboMATCH registration protocol
- Patient must be willing to provide blood samples for research purposes
- Patient must have had at least one prior line of therapy in the metastatic setting
- Patient must have previously undergone taxane therapy (in the metastatic setting)
- Patients who previously responded to prior taxane therapy must have received
their last dose of taxane therapy within 6 months prior to EAY191-E4
registration and have had no other intervening treatment prior to EAY191-E4
registration
- Patients who did not respond to prior taxane therapy are eligible regardless of
the time elapsed since the prior taxane therapy or any other intervening
therapies
- Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of
0-2
- Patient must not have had platinum-resistant epithelial serous ovarian cancer
- Patients must not have neuropathy >= grade 2 within 14 days of
registration/randomization
- Patient must have documented QT interval with Fridericia's correction (QTcF) of =<
450 msec within 8 days prior to EAY191-E4 registration. Patients with a QTcF
interval of >= 450 msec at registration or patients with congenital long QT syndrome
are not eligible
- Patient must not be pregnant or breast-feeding due to the potential harm to an
unborn fetus and possible risk for adverse events in nursing infants with the
treatment regimens being used
- All patients of childbearing potential must have a blood test or urine study
within 14 days prior to registration to rule out pregnancy
- A patient of childbearing potential is defined as anyone, regardless of sexual
orientation or whether they have undergone tubal ligation, who meets the
following criteria: 1) has achieved menarche at some point, 2) has not
undergone a hysterectomy or bilateral oophorectomy; or 3) has not been
naturally postmenopausal (amenorrhea following cancer therapy does not rule out
childbearing potential) for at least 24 consecutive months (i.e., has had
menses at any time in the preceding 24 consecutive months)
- Patient must not expect to conceive or father children by using accepted and
effective method(s) of contraception or by abstaining from sexual intercourse for
the duration of their participation in the study and for at least 3 months after the
last dose of study drug
- Patients must have progressive disease
- Absolute neutrophil count (ANC) >= 1,500/mcL
- Platelets >= 100,000/mcL
- Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (with the
exception of those with Gilbert syndrome, who must have total bilirubin =< 3 x
institutional ULN)
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase
[SGPT]) =< 3 institutional upper limit of normal; < 5.0 x ULN in patients with liver
metastases
- Creatinine clearance > 60 mL/min/1.73 m^2 for patients with creatinine levels > 1.5
mg/dL
- Patient must have the ability to swallow medications
- Patient must have completed any prior therapy ≥ 4 weeks or ≥ 5 half-lives of the
prior agent (whichever is shorter) prior to enrollment on protocol. Prior definitive
radiation should have been completed ≥ 4 weeks prior to enrollment; prior palliative
radiation should have been completed ≥ 2 weeks prior to enrollment. Patients must be
≥ 2 weeks since any investigational agent administered as part of a phase 0 study
(where a sub-therapeutic dose of drug is administered) and should have recovered to
grade 1 or baseline from any toxicities
- Patients with treated brain metastases are eligible if follow-up brain imaging after
central nervous system (CNS)-directed therapy shows no evidence of progression for ≥
1 month after treatment of the brain metastases
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
University of Alabama at Birmingham Cancer Center
Address:
City:
Birmingham
Zip:
35233
Country:
United States
Facility:
Name:
Kingman Regional Medical Center
Address:
City:
Kingman
Zip:
86401
Country:
United States
Facility:
Name:
Stanford Cancer Institute Palo Alto
Address:
City:
Palo Alto
Zip:
94304
Country:
United States
Facility:
Name:
Presbyterian Intercommunity Hospital
Address:
City:
Whittier
Zip:
90602
Country:
United States
Facility:
Name:
UCHealth University of Colorado Hospital
Address:
City:
Aurora
Zip:
80045
Country:
United States
Facility:
Name:
UM Sylvester Comprehensive Cancer Center at Aventura
Address:
City:
Aventura
Zip:
33180
Country:
United States
Facility:
Name:
UM Sylvester Comprehensive Cancer Center at Coral Gables
Address:
City:
Coral Gables
Zip:
33146
Country:
United States
Facility:
Name:
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Address:
City:
Deerfield Beach
Zip:
33442
Country:
United States
Facility:
Name:
University of Miami Miller School of Medicine-Sylvester Cancer Center
Address:
City:
Miami
Zip:
33136
Country:
United States
Facility:
Name:
UM Sylvester Comprehensive Cancer Center at Kendall
Address:
City:
Miami
Zip:
33176
Country:
United States
Facility:
Name:
UM Sylvester Comprehensive Cancer Center at Plantation
Address:
City:
Plantation
Zip:
33324
Country:
United States
Facility:
Name:
Saint Alphonsus Cancer Care Center-Boise
Address:
City:
Boise
Zip:
83706
Country:
United States
Facility:
Name:
Saint Alphonsus Cancer Care Center-Caldwell
Address:
City:
Caldwell
Zip:
83605
Country:
United States
Facility:
Name:
Kootenai Health - Coeur d'Alene
Address:
City:
Coeur d'Alene
Zip:
83814
Country:
United States
Facility:
Name:
Saint Alphonsus Cancer Care Center-Nampa
Address:
City:
Nampa
Zip:
83687
Country:
United States
Facility:
Name:
Kootenai Clinic Cancer Services - Post Falls
Address:
City:
Post Falls
Zip:
83854
Country:
United States
Facility:
Name:
Kootenai Clinic Cancer Services - Sandpoint
Address:
City:
Sandpoint
Zip:
83864
Country:
United States
Facility:
Name:
Advocate Good Shepherd Hospital
Address:
City:
Barrington
Zip:
60010
Country:
United States
Facility:
Name:
Illinois CancerCare-Bloomington
Address:
City:
Bloomington
Zip:
61704
Country:
United States
Facility:
Name:
Illinois CancerCare-Canton
Address:
City:
Canton
Zip:
61520
Country:
United States
Facility:
Name:
Illinois CancerCare-Carthage
Address:
City:
Carthage
Zip:
62321
Country:
United States
Facility:
Name:
Centralia Oncology Clinic
Address:
City:
Centralia
Zip:
62801
Country:
United States
Facility:
Name:
Northwestern University
Address:
City:
Chicago
Zip:
60611
Country:
United States
Facility:
Name:
John H Stroger Jr Hospital of Cook County
Address:
City:
Chicago
Zip:
60612
Country:
United States
Facility:
Name:
Advocate Illinois Masonic Medical Center
Address:
City:
Chicago
Zip:
60657
Country:
United States
Facility:
Name:
AMG Crystal Lake - Oncology
Address:
City:
Crystal Lake
Zip:
60014
Country:
United States
Facility:
Name:
Carle at The Riverfront
Address:
City:
Danville
Zip:
61832
Country:
United States
Facility:
Name:
Cancer Care Specialists of Illinois - Decatur
Address:
City:
Decatur
Zip:
62526
Country:
United States
Facility:
Name:
Decatur Memorial Hospital
Address:
City:
Decatur
Zip:
62526
Country:
United States
Facility:
Name:
Illinois CancerCare-Dixon
Address:
City:
Dixon
Zip:
61021
Country:
United States
Facility:
Name:
Advocate Good Samaritan Hospital
Address:
City:
Downers Grove
Zip:
60515
Country:
United States
Facility:
Name:
Carle Physician Group-Effingham
Address:
City:
Effingham
Zip:
62401
Country:
United States
Facility:
Name:
Crossroads Cancer Center
Address:
City:
Effingham
Zip:
62401
Country:
United States
Facility:
Name:
Advocate Sherman Hospital
Address:
City:
Elgin
Zip:
60123
Country:
United States
Facility:
Name:
Illinois CancerCare-Eureka
Address:
City:
Eureka
Zip:
61530
Country:
United States
Facility:
Name:
Illinois CancerCare-Galesburg
Address:
City:
Galesburg
Zip:
61401
Country:
United States
Facility:
Name:
Advocate South Suburban Hospital
Address:
City:
Hazel Crest
Zip:
60429
Country:
United States
Facility:
Name:
Illinois CancerCare-Kewanee Clinic
Address:
City:
Kewanee
Zip:
61443
Country:
United States
Facility:
Name:
AMG Libertyville - Oncology
Address:
City:
Libertyville
Zip:
60048
Country:
United States
Facility:
Name:
Condell Memorial Hospital
Address:
City:
Libertyville
Zip:
60048
Country:
United States
Facility:
Name:
Illinois CancerCare-Macomb
Address:
City:
Macomb
Zip:
61455
Country:
United States
Facility:
Name:
Carle Physician Group-Mattoon/Charleston
Address:
City:
Mattoon
Zip:
61938
Country:
United States
Facility:
Name:
Cancer Care Center of O'Fallon
Address:
City:
O'Fallon
Zip:
62269
Country:
United States
Facility:
Name:
Advocate Christ Medical Center
Address:
City:
Oak Lawn
Zip:
60453-2699
Country:
United States
Facility:
Name:
Illinois CancerCare-Ottawa Clinic
Address:
City:
Ottawa
Zip:
61350
Country:
United States
Facility:
Name:
Advocate Lutheran General Hospital
Address:
City:
Park Ridge
Zip:
60068
Country:
United States
Facility:
Name:
Illinois CancerCare-Pekin
Address:
City:
Pekin
Zip:
61554
Country:
United States
Facility:
Name:
Illinois CancerCare-Peoria
Address:
City:
Peoria
Zip:
61615
Country:
United States
Facility:
Name:
Illinois CancerCare-Peru
Address:
City:
Peru
Zip:
61354
Country:
United States
Facility:
Name:
Illinois CancerCare-Princeton
Address:
City:
Princeton
Zip:
61356
Country:
United States
Facility:
Name:
Southern Illinois University School of Medicine
Address:
City:
Springfield
Zip:
62702
Country:
United States
Facility:
Name:
Springfield Clinic
Address:
City:
Springfield
Zip:
62702
Country:
United States
Facility:
Name:
Springfield Memorial Hospital
Address:
City:
Springfield
Zip:
62781
Country:
United States
Facility:
Name:
Carle Cancer Center
Address:
City:
Urbana
Zip:
61801
Country:
United States
Facility:
Name:
Illinois CancerCare - Washington
Address:
City:
Washington
Zip:
61571
Country:
United States
Facility:
Name:
Mission Cancer and Blood - Des Moines
Address:
City:
Des Moines
Zip:
50309
Country:
United States
Facility:
Name:
University of Kentucky/Markey Cancer Center
Address:
City:
Lexington
Zip:
40536
Country:
United States
Facility:
Name:
Ochsner Medical Center Jefferson
Address:
City:
New Orleans
Zip:
70121
Country:
United States
Facility:
Name:
Lafayette Family Cancer Center-EMMC
Address:
City:
Brewer
Zip:
04412
Country:
United States
Facility:
Name:
National Institutes of Health Clinical Center
Address:
City:
Bethesda
Zip:
20892
Country:
United States
Facility:
Name:
Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Address:
City:
Ann Arbor
Zip:
48106
Country:
United States
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Address:
City:
Brighton
Zip:
48114
Country:
United States
Facility:
Name:
Trinity Health Medical Center - Brighton
Address:
City:
Brighton
Zip:
48114
Country:
United States
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Canton
Address:
City:
Canton
Zip:
48188
Country:
United States
Facility:
Name:
Trinity Health Medical Center - Canton
Address:
City:
Canton
Zip:
48188
Country:
United States
Facility:
Name:
Chelsea Hospital
Address:
City:
Chelsea
Zip:
48118
Country:
United States
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Address:
City:
Chelsea
Zip:
48118
Country:
United States
Facility:
Name:
Genesee Cancer and Blood Disease Treatment Center
Address:
City:
Flint
Zip:
48503
Country:
United States
Facility:
Name:
Genesee Hematology Oncology PC
Address:
City:
Flint
Zip:
48503
Country:
United States
Facility:
Name:
Genesys Hurley Cancer Institute
Address:
City:
Flint
Zip:
48503
Country:
United States
Facility:
Name:
Hurley Medical Center
Address:
City:
Flint
Zip:
48503
Country:
United States
Facility:
Name:
University of Michigan Health - Sparrow Lansing
Address:
City:
Lansing
Zip:
48912
Country:
United States
Facility:
Name:
Trinity Health Saint Mary Mercy Livonia Hospital
Address:
City:
Livonia
Zip:
48154
Country:
United States
Facility:
Name:
Henry Ford Saint John Hospital - Macomb Medical
Address:
City:
Macomb
Zip:
48044
Country:
United States
Facility:
Name:
Huron Gastroenterology PC
Address:
City:
Ypsilanti
Zip:
48106
Country:
United States
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Address:
City:
Ypsilanti
Zip:
48197
Country:
United States
Facility:
Name:
Sanford Joe Lueken Cancer Center
Address:
City:
Bemidji
Zip:
56601
Country:
United States
Facility:
Name:
Saint Francis Medical Center
Address:
City:
Cape Girardeau
Zip:
63703
Country:
United States
Facility:
Name:
Parkland Health Center - Farmington
Address:
City:
Farmington
Zip:
63640
Country:
United States
Facility:
Name:
Missouri Baptist Medical Center
Address:
City:
Saint Louis
Zip:
63131
Country:
United States
Facility:
Name:
Sainte Genevieve County Memorial Hospital
Address:
City:
Sainte Genevieve
Zip:
63670
Country:
United States
Facility:
Name:
Missouri Baptist Sullivan Hospital
Address:
City:
Sullivan
Zip:
63080
Country:
United States
Facility:
Name:
BJC Outpatient Center at Sunset Hills
Address:
City:
Sunset Hills
Zip:
63127
Country:
United States
Facility:
Name:
Community Hospital of Anaconda
Address:
City:
Anaconda
Zip:
59711
Country:
United States
Facility:
Name:
Billings Clinic Cancer Center
Address:
City:
Billings
Zip:
59101
Country:
United States
Facility:
Name:
Bozeman Health Deaconess Hospital
Address:
City:
Bozeman
Zip:
59715
Country:
United States
Facility:
Name:
Benefis Sletten Cancer Institute
Address:
City:
Great Falls
Zip:
59405
Country:
United States
Facility:
Name:
Logan Health Medical Center
Address:
City:
Kalispell
Zip:
59901
Country:
United States
Facility:
Name:
Community Medical Center
Address:
City:
Missoula
Zip:
59804
Country:
United States
Facility:
Name:
OptumCare Cancer Care at Seven Hills
Address:
City:
Henderson
Zip:
89052
Country:
United States
Facility:
Name:
OptumCare Cancer Care at Charleston
Address:
City:
Las Vegas
Zip:
89102
Country:
United States
Facility:
Name:
OptumCare Cancer Care at Fort Apache
Address:
City:
Las Vegas
Zip:
89148
Country:
United States
Facility:
Name:
Roswell Park Cancer Institute
Address:
City:
Buffalo
Zip:
14263
Country:
United States
Facility:
Name:
Mount Sinai Hospital
Address:
City:
New York
Zip:
10029
Country:
United States
Facility:
Name:
Sanford Bismarck Medical Center
Address:
City:
Bismarck
Zip:
58501
Country:
United States
Facility:
Name:
Sanford Broadway Medical Center
Address:
City:
Fargo
Zip:
58122
Country:
United States
Facility:
Name:
Sanford Roger Maris Cancer Center
Address:
City:
Fargo
Zip:
58122
Country:
United States
Facility:
Name:
Dayton Physician LLC - Englewood
Address:
City:
Dayton
Zip:
45415
Country:
United States
Facility:
Name:
Kettering Medical Center
Address:
City:
Kettering
Zip:
45429
Country:
United States
Facility:
Name:
Toledo Clinic Cancer Centers-Toledo
Address:
City:
Toledo
Zip:
43623
Country:
United States
Facility:
Name:
University of Oklahoma Health Sciences Center
Address:
City:
Oklahoma City
Zip:
73104
Country:
United States
Facility:
Name:
Saint Alphonsus Cancer Care Center-Ontario
Address:
City:
Ontario
Zip:
97914
Country:
United States
Facility:
Name:
Providence Portland Medical Center
Address:
City:
Portland
Zip:
97213
Country:
United States
Facility:
Name:
Providence Saint Vincent Medical Center
Address:
City:
Portland
Zip:
97225
Country:
United States
Facility:
Name:
Sanford Cancer Center Oncology Clinic
Address:
City:
Sioux Falls
Zip:
57104
Country:
United States
Facility:
Name:
Sanford USD Medical Center - Sioux Falls
Address:
City:
Sioux Falls
Zip:
57117-5134
Country:
United States
Facility:
Name:
M D Anderson Cancer Center
Address:
City:
Houston
Zip:
77030
Country:
United States
Facility:
Name:
Swedish Cancer Institute-Edmonds
Address:
City:
Edmonds
Zip:
98026
Country:
United States
Facility:
Name:
Swedish Cancer Institute-Issaquah
Address:
City:
Issaquah
Zip:
98029
Country:
United States
Facility:
Name:
Valley Medical Center
Address:
City:
Renton
Zip:
98055
Country:
United States
Facility:
Name:
Swedish Medical Center-First Hill
Address:
City:
Seattle
Zip:
98122
Country:
United States
Facility:
Name:
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
Address:
City:
Yakima
Zip:
98902
Country:
United States
Facility:
Name:
ThedaCare Regional Cancer Center
Address:
City:
Appleton
Zip:
54911
Country:
United States
Facility:
Name:
Aurora Cancer Care-Grafton
Address:
City:
Grafton
Zip:
53024
Country:
United States
Facility:
Name:
Aurora BayCare Medical Center
Address:
City:
Green Bay
Zip:
54311
Country:
United States
Facility:
Name:
Gundersen Lutheran Medical Center
Address:
City:
La Crosse
Zip:
54601
Country:
United States
Facility:
Name:
University of Wisconsin Carbone Cancer Center - University Hospital
Address:
City:
Madison
Zip:
53792
Country:
United States
Facility:
Name:
Aurora Bay Area Medical Group-Marinette
Address:
City:
Marinette
Zip:
54143
Country:
United States
Facility:
Name:
Aurora Saint Luke's Medical Center
Address:
City:
Milwaukee
Zip:
53215
Country:
United States
Facility:
Name:
Aurora Sinai Medical Center
Address:
City:
Milwaukee
Zip:
53233
Country:
United States
Facility:
Name:
Vince Lombardi Cancer Clinic - Oshkosh
Address:
City:
Oshkosh
Zip:
54904
Country:
United States
Facility:
Name:
Vince Lombardi Cancer Clinic-Sheboygan
Address:
City:
Sheboygan
Zip:
53081
Country:
United States
Facility:
Name:
Aurora Medical Center in Summit
Address:
City:
Summit
Zip:
53066
Country:
United States
Facility:
Name:
Vince Lombardi Cancer Clinic-Two Rivers
Address:
City:
Two Rivers
Zip:
54241
Country:
United States
Facility:
Name:
Aurora Cancer Care-Milwaukee West
Address:
City:
Wauwatosa
Zip:
53226
Country:
United States
Facility:
Name:
Aurora West Allis Medical Center
Address:
City:
West Allis
Zip:
53227
Country:
United States
Start date:
July 14, 2023
Completion date:
July 1, 2025
Lead sponsor:
Agency:
National Cancer Institute (NCI)
Agency class:
NIH
Source:
National Cancer Institute (NCI)
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05554341
